23 and Me's Struggles: From Stardom to Nasdaq Delisting

23 and Me faces delisting from Nasdaq as it struggles with financial losses and privacy concerns, putting its future at risk.

### The Rise and Fall of 23 and Me: From Genetic Testing Pioneer to Nasdaq Struggles
* 🧬 23 and Me, once valued at **$6 billion**, is now facing delisting from Nasdaq as its share price **falls below $1**, with a November deadline looming for an **action plan**.
* 📉 Founded in 2006 by Anne Wojcicki and others, the company aimed to **democratize access to genetic information** through affordable DNA tests, achieving **significant early success** and **FDA approval** by 2015.
* 🎉 The company gained popularity with marketing strategies like the 2008 "**spit party**" during New York Fashion Week, and by 2016, the cost of their kits had dropped to **$99**, attracting **millions of customers**.
* 🔍 However, privacy concerns arose after a high-profile case involving genetic data, and sales **plummeted by 46% in 2019**, leading to layoffs as the company struggled to find a **sustainable business model**.
* 💔 Despite ambitions to transition into therapeutics, 23 and Me reported a **$312 million loss** in fiscal 2023, and in September 2023, the company faced a **data breach affecting nearly 7 million users**.
* 📅 By mid-September, all board members resigned due to frustrations with Wojcicki's leadership, and the company received another Nasdaq warning, emphasizing the **urgency for a strategic turnaround**.
* 🔄 Wojcicki proposed taking the company private, but her plan was rejected, and the company announced a **reverse stock split** in an attempt to **stabilize its share price**.
* 🗣 As uncertainty looms, Wojcicki is committed to finding **new independent directors** and insists that **customer genetic data will remain confidential** amid ongoing struggles.

23 and Me on the verge of getting delisted from the Nasdaq. Drama has been unfolding this week. It's only set to ramp up. 23 me built a multi-billion dollar brand off of collecting people's spit. The idea was that people could take control of their health by learning about their genetics. And it took off. But just two years after going public, the company went from being valued at $6 billion to trading below $1. Now 23 and Me is rapidly approaching a November deadline to propose an action plan or be delisted from the Nasdaq. So how did one of the most disruptive startups of the 2000s go from Silicon Valley stardom to a penny stock? And can its CEO save the company from collapse? 23 and Me was founded in 2006 by Anne Wojcicki, Linda Avey, and Paul Cusenza. The mission of the company was pretty straightforward.

They set out to give consumers an easy and inexpensive way to access their genetic information. So, they did this by developing a DNA test that you can really kind of take from anywhere. It's an online test. You go online, you order it, we send you a little tube, you spit in the tube, you send it back to us, we extract the DNA out of that, and then we look at a million data points in your DNA. And from that, we can tell you a ton of information about your health and also about your ancestry today. This isn't all that different from competitors like ancestry and Family Tree DNA, but 23 and Me was one of the first to bring genetic testing directly to consumers at an affordable price. By 2012, the company was able to lower the cost of its kit from $999 to $299. This was thanks to capital from high-profile backers.

One of them was Wojcicki's then partner, Google co-founder Sergey Brin. Anne is a really connected person in Silicon Valley, and she understood how to leverage star power in a way that would also help to build 23 and Me brand. So in 2008, for instance, the company famously held what they called a spit party. So during New York Fashion Week, a bunch of celebrities and high-profile guests came and gave a saliva sample, generated a ton of buzz and attention around the company. Sales started booming. The company announced it had Genotyped 1 million customers, and in 2015, the company gained FDA approval to provide more in-depth health information to customers, and in 2016, it finally lowered the price of its kits to $99. I think that. Every technology, it takes a while for adoption. Now it's suddenly become relatively normal. People share their stories online.

I just took a DNA test. Celebrity endorsements kept pouring in, and the company was named one of CNBC's top disruptors of 2018. And thanks so much for joining us here today. Congrats on your spot on the list in the top ten, no less. And during this period, 23 and Me was quietly building a massive database of genetic information. You may wonder what happens to all that genetic data that people send in to the company. Well, the Silicon Valley giant now has the world's largest database for genetic research. 4 million customers have given them permission to use their DNA to study genetic diseases. The company partnered with several pharmaceutical companies and universities to study genetic links in diseases like depression. But customers began to raise concerns around privacy in 2018. A serial killer cold case was solved using DNA from 23 and Me. The company had also started to face

problems with recurring revenue. There hasn't been a sustainable business model. It's the kind of test that you take. Once sales of 23 and Me test kits declined 46% in 2019 compared to a year earlier. The company laid off 100 employees in an effort to cut costs, but Wojcicki still hoped to move the company beyond selling DNA tests. And so now we're really at a point in time where I'm ready to, you know, explode like there's huge opportunities on therapeutics and huge opportunities for our consumer business. So 23 and Me wanted to leverage this genetic database that it had accumulated because, you know, millions of people are taking this test. They have a lot of valuable data. But the fact of the matter is that therapeutics, drug development, drug discovery, it's just really hard.

And extremely expensive. One recent study estimates that drug development in the US can range anywhere from $314 million to $4.46 billion, and can take years to reach patients. Wojcicki's solution was to take a bet on the public market. 23 and Me going public today through a merger with Richard Branson's SPAC, VG Acquisition Corp. In 2021, 23 and Me went public on the Nasdaq and was valued around $3.5 billion. At the time, there was a boom in SPACs, or special purpose acquisition companies when 23 and Me went public in 2021. The coronavirus pandemic is in full swing and the market is booming. So healthcare companies, tech companies, they're raising money really, really quickly at really high valuations. A lot of founders who I talked to at this time like to joke that it's like money is free during this

period. Going public helped fuel research and development efforts despite falling sales. I have this incredible drug discovery team and platform. I have over 40 programs underway, and I want to scale all of it. So, I imagine us in the future, ten years from now, a very robust consumer business and a very robust therapeutic side. So, we absolutely aspire to be a full-fledged therapeutic development company that is going to bring those programs to our customers. But by 2022, interest rates had begun to rise, and the company was struggling to raise enough money to fund its research and development. The company ended the fiscal 2023 year at a $312 million loss. All of those ambitions were there. She was trying to create some recurring revenue by a subscription model where users could tap into the more data that they got, and that data is really powerful. But there was always this problem.

She couldn't really sell it. And it turns out, surprise, surprise, that health care, that drug development, is really hard to do. In September of 2023, the share price slid below $1, and the company received a deficiency letter from the Nasdaq. Then the privacy concerns returned. Genetic testing company 23 and Me says hackers accessed the data of nearly 7 million people during an attack in October. That total far more than previously acknowledged accessing user data, including genetic profiles. By 2024, the company announced it was shuttering its drug development team and instead focusing on money-making obesity drugs via telehealth. Its most recent earnings report shows a net loss of $667 million. In March, 23 and Me established a special committee of independent directors to help Wojcicki figure out a path forward for the company to boost its share price.

And it's important to note here that Anne is on the board of 23 and Me, but she was not involved with this special committee in April and signals to the special committee that she's going to submit a proposal to try to take the company private. Unfortunately for her, the very next day, the special committee rejects this proposal. The committee gave Wojcicki until September to offer a revised proposal, but they never received one. Wojcicki wants to take back control of her company three years after going public via Spac, and she's rejecting outside consultants. Now she's abandoned by her board. By mid-September, all seven board members resigned, citing frustration with Wojcicki's strategic differences and concentrated voting power. Then the company received yet another warning letter from the Nasdaq saying that Wojcicki needs to come up

with an action plan before November 4th. It certainly is a big question mark as to exactly what will happen next, but a lot of it feels really up to Anne at this point. She, in a memo to employees in September, said she's going to immediately start looking for new independent directors to join the board. Wojcicki has said in a memo to the SEC that she intends to take the company private and is not interested in third-party bids. In October, the company also announced a reverse stock split in an effort to boost its share price. As for what will happen to the customer genetic data if the company is sold? CNBC reached out to 23 and Me for comment, and a spokesperson emailed back saying that the company remains committed to going private and that it will not share customer data with third parties without their consent.

What Happened To 23andMe?

Welcome to the official YouTube channel for CNBC. From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.

For real-time news updates from around the world, visit: http://www.cnbc.com

For CNBC's primetime TV lineup, visit http://tv.cnbc.com

For CNBC's International YouTube channel, visit: http://www.youtube.com/cnbcinternational

CNBC

23 and Me is facing delisting from the Nasdaq after a dramatic fall from a $6 billion valuation to trading below $1 in just two years.

The company's unique business model, offering affordable genetic testing through a simple spit sample, initially drove its success.

Founded in 2006 by Anne Wojcicki, Linda Avey, and Paul Cusenza, 23 and Me aimed to empower consumers with their genetic information, but now struggles to propose a viable action plan before the November deadline.

The Impact of Anne Wojcicki on 23andMe's Success

Anne Wojcicki, with her connections in Silicon Valley, leveraged star power to build 23andMe's brand, famously hosting a "spit party" during New York Fashion Week in 2008.

The company quickly gained traction, genotyping 1 million customers and receiving FDA approval for in-depth health information by 2015.

However, concerns around privacy arose in 2018 after a cold case was solved using the company's DNA data, leading to increased scrutiny.

23 and Me struggled with a sustainable business model, experiencing a 46% decline in test kit sales in 2019, leading to employee layoffs.

The company aimed to leverage its genetic database for therapeutics and consumer business growth, but drug development proved to be challenging and expensive.

23 and Me went public in 2021 through a merger with Richard Branson's SPAC, benefiting from the booming market during the pandemic.

Struggles of 23andMe: From Ambitious Drug Development to Telehealth

23andMe aimed to scale its drug discovery programs but struggled financially, ending fiscal 2023 with a $312 million loss.

The company's share price fell below $1 in September 2023, leading to a deficiency letter from Nasdaq, and it faced privacy concerns after a data breach affected nearly 7 million users.

By 2024, 23andMe shifted its focus to telehealth and obesity drugs, announcing the closure of its drug development team and reporting a net loss of $667 million.

Anne Wojcicki, a board member of 23 and Me, proposed taking the company private but was rejected by the special committee.

By mid-September, all seven board members resigned due to frustration with Wojcicki's leadership.

The company faced a warning from Nasdaq and announced a reverse stock split, while Wojcicki expressed her intention to find new independent directors and committed to not sharing customer genetic data with third parties.